{"id":1012160,"date":"2026-10-21T07:04:22","date_gmt":"2026-10-21T11:04:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/"},"modified":"2026-10-21T07:04:22","modified_gmt":"2026-10-21T11:04:22","slug":"an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/","title":{"rendered":"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18<sup>th<\/sup> International Congress on Myeloproliferative Neoplasms<\/b><\/p>\n<p>MENLO PARK, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18<sup>th<\/sup> International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York.<\/p>\n<p><b>Poster Session Details<br \/>\n<br \/><\/b>Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV<br \/>\n<br \/>Date: Thursday, October 29, 2026<br \/>\n<br \/>Time: 5:45-7:15pm ET<br \/>\n<br \/>Poster number: 148<\/p>\n<p><b>About AN2 Therapeutics<\/b><\/p>\n<p>\nAN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261021103616\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261021103616\/en\/<\/a><\/span><\/p>\n<p><b>Company Contact:<br \/>\n<\/b><br \/>Lucy O. Day<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:l.day@an2therapeutics.com\">l.day@an2therapeutics.com<\/a><\/p>\n<p><b>Investor and Media Contact:<br \/>\n<\/b><br \/>Anne Bowdidge<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@an2therapeutics.com\">ir@an2therapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases Clinical Trials Biotechnology Health Pharmaceutical General Health Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261021103616\/en\/1863965\/3\/AN2_Therapeutics_Press_Release_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York. Poster Session Details Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV Date: Thursday, October 29, 2026 Time: 5:45-7:15pm ET Poster number: 148 About &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012160","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York. Poster Session Details Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV Date: Thursday, October 29, 2026 Time: 5:45-7:15pm ET Poster number: 148 About &hellip; Continue reading &quot;AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-21T11:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms\",\"datePublished\":\"2026-10-21T11:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/\",\"name\":\"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-21T11:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/","og_locale":"en_US","og_type":"article","og_title":"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms - Market Newsdesk","og_description":"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York. Poster Session Details Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV Date: Thursday, October 29, 2026 Time: 5:45-7:15pm ET Poster number: 148 About &hellip; Continue reading \"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-21T11:04:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms","datePublished":"2026-10-21T11:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/"},"wordCount":279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/","name":"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-21T11:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261021103616r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-present-phase-2-design-for-epetraborole-in-polycythemia-vera-at-the-18th-international-congress-on-myeloproliferative-neoplasms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012160"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012160\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}